Alteogen challenges to KRW 2 trillion hemophilia biomedicine ‘NovoSeven’

Published: 2016-12-01 16:28:00
Updated: 2016-12-01 11:50:42

Alteogen Inc.(CEO Soon-Jae Park) held an agreement ceremony on the 29th of November as its long-acting hemophilia treatment being developed, ‘ALT-Q2,’ was selected as a project to develop a substance candidate for a preclinical trial from the Korea Drug Development Fund(CEO Sang-Aun Joo).



- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.